MedTrace Logo

The Impact of Contraception on Postpartum Weight Loss

NCT02144259 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-02-17

Study results available
· View outcomes & findings →

Summary

This is a prospective mixed methods study to assess weight changes in women randomized to receive Implanon ® or Depo Provera® (DMPA) immediately postpartum compared to women who choose non-hormonal contraception or no contraception immediately postpartum. After enrollment, subjects return for a visit at 3, 6 and 12 months postpartum to be asked a series of questions, take a pregnancy test, and be weighed. Total length of participation for each subject is 1 year or until pregnancy.

Conditions

  • Weight

Interventions

DRUG

DMPA immediately postpartum

DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.

DRUG

Implanon immediately postpartum

Implanon ® is a subdermal implant that contains 68mg of etonogestrel.

Sponsors & Collaborators

Principal Investigators

  • Courtney A Schreiber, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02144259 on ClinicalTrials.gov